My reference to Anavex being “radioactive” was merely to point out that given a choice, the FDA would probably prefer to not deal with a company that just fired their CEO for cause. It casts a cloud over things until the new management team can reassure the investment community and other stakeholders what the damage was—and what the future prospects are.
We really don’t know these answers until we hear from the new leadership—the sooner, the better.
Don’t get upset with me—I have nothing to do with the predicament we are in, other than being an unfortunate shareholder like many on this board. I was hoping to be wrong about Missling, but sadly I wasn’t.
My mother always told me, if someone shows you over and over again who they are—believe them. Missling’s repetitive behavior of being aloof, arrogant, poorly-spoken, and obtuse were huge hints at the train wreck he really was. This man had no business being a leader of a lemonade stand—no less a Nasdaq biotechnology company. Shame on this BOD for not recognizing this a lot sooner.
Market Data 
Markets 
AI
